Get the Stockscreener App
12.18
2.78%
0.33
Greenwich Lifesciences Inc stock is traded at $12.18, with a volume of 37,473.
It is up +2.78% in the last 24 hours and up +9.34% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$11.85
Open:
$11.92
24h Volume:
37,473
Relative Volume:
0.70
Market Cap:
$162.83M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-17.40
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+0.08%
1M Performance:
+9.34%
6M Performance:
+1.92%
1Y Performance:
-13.86%
1-Day Range:
$11.92
$12.33
1-Week Range:
$11.41
$12.39
52-Week Range:
$8.06
$16.50
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
12.18 | 160.55M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Can trapped investors hope for a rebound in Greenwich LifeSciences Inc.Trade Entry Summary & High Conviction Buy Zone Picks - Newser
Greenwich LifeSciences stock initiated at Outperform by Noble Capital - Investing.com
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences - GlobeNewswire
Signal strength of Greenwich LifeSciences Inc. stock in tech scannersMarket Rally & Smart Money Movement Tracker - Newser
Understanding Greenwich LifeSciences Inc.’s price movementWeekly Earnings Recap & Accurate Intraday Trading Signals - Newser
Greenwich LifeSciences Inc.’s volatility index tracking explainedMarket Sentiment Review & Entry Point Confirmation Signals - Newser
Predicting Greenwich LifeSciences Inc. trend using moving averages2025 Market Overview & Technical Pattern Based Signals - Newser
Real time scanner hits for Greenwich LifeSciences Inc. explainedJuly 2025 Summary & Real-Time Volume Analysis Alerts - Newser
Should you wait for a breakout in Greenwich LifeSciences Inc.Weekly Profit Report & Community Trade Idea Sharing - Newser
What makes Greenwich LifeSciences Inc. stock price move sharplyWeekly Trend Report & Free Growth Oriented Trading Recommendations - Newser
Can Greenwich LifeSciences Inc. hit a new high this monthPortfolio Update Report & Community Trade Idea Sharing Platform - Newser
BiomX’s mid-stage cystic fibrosis trial put on clinical hold; Santen makes a deal with RemeGen - Endpoints News
Applying big data sentiment scoring on Greenwich LifeSciences Inc.2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Will Greenwich LifeSciences Inc. Benefit From Sector Tailwinds2025 Technical Patterns & Accurate Technical Buy Alerts - theviewers.co.kr
Greenwich LifeSciences brings clinical trial management in-house - Investing.com
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team - The Manila Times
Vertical Integration Reshapes Biotech Innovation: Greenwich LifeSciences' Strategic Shift and Its Implications for Investors - AInvest
Greenwich LifeSciences to Build Internal Clinical Operations Team - AInvest
Cost-Cutting Strategy: Greenwich LifeSciences Brings Phase III Breast Cancer Trial In-House for Enhanced Control - Stock Titan
How to build a dashboard for Greenwich LifeSciences Inc. stockJuly 2025 Short Interest & AI Enhanced Trade Execution Alerts - Newser
How to read the order book for Greenwich LifeSciences Inc.Dividend Hike & Risk Controlled Daily Trade Plans - Newser
Forecasting Greenwich LifeSciences Inc. price range with options dataJuly 2025 Short Interest & AI Powered Market Entry Strategies - Newser
Greenwich LifeSciences Inc. stock prediction for this weekTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
What indicators show strength in Greenwich LifeSciences Inc.Share Buyback & Free Daily Entry Point Trade Alerts - Newser
Insiders Hold Significant Stake in Greenwich LifeSciences, Inc. - AInvest
Owning 53% in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) means that insiders are heavily invested in the company's future - Yahoo Finance
Is Greenwich LifeSciences Inc. forming a reversal pattern2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - Newser
What machine learning models say about Greenwich LifeSciences Inc.2025 Valuation Update & Safe Capital Growth Tips - Newser
How Greenwich LifeSciences Inc. stock performs during market volatilityQuarterly Investment Review & Free Reliable Trade Execution Plans - Newser
Greenwich Lifesciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why Greenwich LifeSciences Inc. stock attracts strong analyst attentionMarket Performance Recap & Advanced Technical Signal Analysis - Newser
Greenwich LifeSciences Inc.’s Beta Climbs After Market VolatilityQuarterly Market Summary & Low Risk Entry Point Guides - newsyoung.net
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
| Patel Snehal | CEO and CFO |
Jan 06 '25 |
Buy |
13.31 |
1,100 |
14,641 |
5,548,202 |
| Patel Snehal | CEO and CFO |
Jan 03 '25 |
Buy |
12.95 |
3,400 |
44,030 |
5,547,102 |
| Patel Snehal | CEO and CFO |
Jan 02 '25 |
Buy |
11.97 |
2,000 |
23,940 |
5,543,702 |
| Patel Snehal | CEO and CFO |
Dec 31 '24 |
Buy |
11.36 |
2,400 |
27,264 |
5,541,702 |
| Patel Snehal | CEO and CFO |
Dec 30 '24 |
Buy |
11.12 |
3,200 |
35,584 |
5,539,302 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):